Ford Robert B 4

What Happened

• Robert B. Ford, Chairman and CEO of Abbott Laboratories (ABT), received two equity awards on Feb 24, 2026: 83,464 restricted shares and a 344,066-share award reported as a derivative. Both grants are reported at a $0 per-share acquisition price (typical for incentive awards).

Key Details

• Transaction date: Feb 24, 2026; Form 4 filed Feb 26, 2026 (two days later).
• Reported amounts and prices: 83,464 shares acquired at $0.00; 344,066 shares (derivative) acquired at $0.00.
• Footnotes of note:
  • F1: The award is a performance-based restricted stock award under Abbott’s 2017 Incentive Stock Program with a 3-year term; no more than 1/3 vests in any year and vesting is tied to a minimum return-on-equity target. The award allows share withholding for taxes.
  • F3: The 344,066 derivative relates to an employee stock option under the 2017 plan that vests in annual increments of 114,688 on Feb 24, 2027; 114,689 on Feb 24, 2028; and 114,689 on Feb 24, 2029.
  • F2: Some holdings are held in the Ford Family Trust (reporting person is co‑trustee).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: Filed Feb 26 for a Feb 24 transaction; generally within the two-business-day Form 4 deadline.

Context

• These are grants/awards (not open-market purchases or sales). Performance-based restricted shares and time/vesting schedule on options mean economic value depends on future vesting and achievement of targets — not an immediate liquidity event.
• For the option-like award (344,066 shares), vesting occurs over 2027–2029; there is no indication in this filing that any shares were immediately sold.